Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 18/20 | 1.00 |
| ▸ | BCHE | P06276 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quilostigmine SCHEMBL8989362 | 1.00 | ACHE (1.00) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| Quilostigmine SCHEMBL9150209 | 1.00 | ACHE (1.00) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| Quilostigmine SCHEMBL8989327 | 1.00 | ACHE (1.00) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| Quilostigmine SCHEMBL8989330 | 1.00 | ACHE (1.00) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| Quilostigmine SCHEMBL29868383 | 1.00 | ACHE (1.00) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9204860 | 0.80 | ACHE (0.79) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL10109481 | 0.79 | ACHE (0.77) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9204862 | 0.79 | ACHE (0.77) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9204867 | 0.79 | ACHE (0.77) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL8199132 | 0.79 | ACHE (0.77) | ACHEBCHEALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2200610-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | Acadia Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | claimed |
| WO-2009039460-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| WO-2009039461-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | claimed |
| US-20080103126-A1 | Medicinal compositions improving brain function and method for improving brian function | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-05-01 | — | — | US | claimed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050250843-A1 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-11-10 | — | — | US | claimed |
| EP-1514542-A1 | MEDICINAL COMPOSITIONS IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-16 | — | — | EP | claimed |
| US-20030130303-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER INC. | 2003-07-10 | — | — | US | claimed |
| EP-1280554-A2 | A PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF DISEASES OF COGNITIVE DYSFUNTION IN A MAMMAL | Pfizer Products Inc. (US) | 2003-02-05 | — | — | EP | claimed |
| WO-2001085145-A2 | A PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF DISEASES OF COGNITIVE DYSFUNCTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-20010036949-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | ACHE 2/4885BCHE 5/4885ALDH1A1 1168/4885 |
| US-20050250843-A1 | Medicinal compositions improving brain function and method for improving brain function | CHRM2, ACHE, CHAT | ACHE 2/4885BCHE 18/4885ALDH1A1 1765/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | ACHE 3/4885BCHE 14/4885ALDH1A1 1189/4885 |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | ACHE 2/4885BCHE 5/4885ALDH1A1 1168/4885 |
| US-20080103126-A1 | Medicinal compositions improving brain function and method for improving brian function | CHRM2, ACHE, CHRM1 | ACHE 2/4885BCHE 4/4885ALDH1A1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.